Compare Eiken Chemical Co., Ltd. with Similar Stocks
Dashboard
1
High Management Efficiency with a high ROE of 9.70%
2
Company has very low debt and has enough cash to service the debt requirements
3
Poor long term growth as Net Sales has grown by an annual rate of 2.07% over the last 5 years
4
Flat results in Dec 25
5
With ROE of 5.67%, it has a very attractive valuation with a 1.78 Price to Book Value
6
Market Beating performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
JPY 84,696 Million (Small Cap)
31.00
NA
0.00%
-0.15
9.43%
1.93
Revenue and Profits:
Net Sales:
10,947 Million
(Quarterly Results - Dec 2025)
Net Profit:
743 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
44.86%
0%
44.86%
6 Months
36.76%
0%
36.76%
1 Year
53.99%
0%
53.99%
2 Years
76.09%
0%
76.09%
3 Years
110.73%
0%
110.73%
4 Years
87.93%
0%
87.93%
5 Years
54.35%
0%
54.35%
Eiken Chemical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
2.07%
EBIT Growth (5y)
-8.29%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.15
Sales to Capital Employed (avg)
0.82
Tax Ratio
25.51%
Dividend Payout Ratio
81.76%
Pledged Shares
0
Institutional Holding
0.35%
ROCE (avg)
17.07%
ROE (avg)
9.70%
Valuation key factors
Factor
Value
P/E Ratio
31
Industry P/E
Price to Book Value
1.78
EV to EBIT
23.70
EV to EBITDA
12.80
EV to Capital Employed
1.91
EV to Sales
1.75
PEG Ratio
NA
Dividend Yield
0.03%
ROCE (Latest)
8.07%
ROE (Latest)
5.67%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Bullish
Shareholding Snapshot : Dec 2016
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.35%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
10,947.00
10,233.00
6.98%
Operating Profit (PBDIT) excl Other Income
1,732.00
1,530.00
13.20%
Interest
5.00
5.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
743.00
2,379.00
-68.77%
Operating Profit Margin (Excl OI)
96.00%
90.70%
0.53%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 6.98% vs 0.35% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is -68.77% vs 296.50% in Sep 2025
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
40,539.00
40,052.00
1.22%
Operating Profit (PBDIT) excl Other Income
5,554.00
5,705.00
-2.65%
Interest
17.00
17.00
Exceptional Items
-250.00
0.00
Consolidate Net Profit
2,228.00
2,634.00
-15.41%
Operating Profit Margin (Excl OI)
74.00%
84.40%
-1.04%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 1.22% vs -7.44% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is -15.41% vs -54.08% in Mar 2024
About Eiken Chemical Co., Ltd. 
Eiken Chemical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






